TRT claims from @anabolicchemist: what the science says

What's this video probably claiming?

A creator going by @anabolicchemist with nearly 100K views on a TRT video is almost certainly making some combination of the following assertions: that testosterone replacement therapy produces dramatic body composition changes, that standard clinical dosing is too conservative, that "optimizing" testosterone levels above the clinical normal range is beneficial rather than risky, or that self-managed TRT protocols outperform physician-supervised ones. The "anabolic" framing in the handle is a tell. This creator is likely positioning TRT not as a treatment for diagnosed hypogonadism but as a performance and optimization tool available to anyone who wants to feel better or build muscle faster. That framing has real consequences for how viewers interpret dosing, risk, and what "normal" actually means medically.

What does the science actually show?

The clinical literature on TRT is more nuanced than most TikTok content suggests. The landmark Testosterone Trials (Snyder et al., 2016, NEJM) enrolled men 65 and older with confirmed hypogonadism and found modest improvements in sexual function and bone density, but the cardiovascular signal was concerning enough to prompt continued study. The TRAVERSE trial (Lincoff et al., 2023, NEJM) followed over 5,200 men and found testosterone non-inferior to placebo on major cardiovascular events, which is reassuring, but the trial excluded men at highest cardiac risk. For body composition, Bhasin et al. (2001, NEJM) showed dose-dependent muscle gains at supraphysiologic doses of 600mg testosterone enanthate weekly, but that dose is roughly 4-6 times what most TRT protocols prescribe. The gains come with a risk profile most clinicians would not sanction.

Where does the social media noise diverge from clinical reality?

The biggest gap is between "optimizing" testosterone and treating hypogonadism. Clinical hypogonadism is defined as consistently low total testosterone (generally below 300 ng/dL per Endocrine Society guidelines) combined with symptoms. Social media TRT content routinely encourages men with levels of 400-500 ng/dL to seek treatment because they feel fatigued or because higher is supposedly better. There is no quality evidence supporting that. A second gap is erythrocytosis risk. Testosterone raises hematocrit, and levels above 54% significantly increase thrombotic risk. Most TikTok TRT content never mentions this. Third, the content almost never addresses fertility. Exogenous testosterone suppresses LH and FSH, causing testicular atrophy and azoospermia in a majority of users. Wenker et al. (2015, Journal of Urology) documented this extensively.

What should you actually know?

TRT is a legitimate, FDA-approved therapy for men with documented hypogonadism. It is not a general wellness intervention or a shortcut to better body composition for men with normal testosterone levels. Before starting TRT, a clinician should confirm low levels on at least two morning blood draws, evaluate for secondary causes like pituitary dysfunction or obesity, and discuss fertility implications in detail. Monitoring during therapy should include hematocrit, PSA, and symptom tracking at regular intervals. The Endocrine Society's 2018 clinical practice guidelines are the most evidence-based reference point available. Any content that frames TRT as something to self-initiate, super-dose, or use without diagnosis should be viewed with significant skepticism. The downstream risks, including polycythemia, cardiovascular strain, infertility, and suppression of the hypothalamic-pituitary-gonadal axis, are real and not minor.